SCHEMBL7189908

SCHEMBL7189908

O=PC(C(=O)c1c(Cl)cccc1Cl)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
PBRM1 Q86U86 1/20 0.41
FABP3 P05413 1/20 0.39
FABP4 P15090 1/20 0.39
FEN1 P39748 1/20 0.39
KCNQ2 O43526 1/20 0.38
CASR P41180 1/20 0.37
ACP3 P15309 1/20 0.37
GPR55 Q9Y2T6 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HPGD P15428 1/20 0.36
CYP2D6 P10635 1/20 0.35
SRC P12931 1/20 0.35
LMNA P02545 2/20 0.35
TSHR P16473 1/20 0.35
AKR1B1 P15121 1/20 0.35
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189027 0.89 FABP3 (0.43) ALDH1A1PBRM1FABP3FABP4KCNQ2
SCHEMBL7185609 0.85 FABP4 (0.46) ALDH1A1FABP4TDP1HPGDLMNA
SCHEMBL7175012 0.79 L3MBTL1 (0.46) FABP3FABP4ACP3TDP1L3MBTL1
SCHEMBL7182204 0.76 KCNQ2 (0.44) ALDH1A1PBRM1FABP3FABP4FEN1
SCHEMBL7185486 0.76 CA12 (0.51) ALDH1A1FABP4TDP1HPGDLMNA
SCHEMBL7181409 0.74 KCNQ2 (0.44) ALDH1A1PBRM1FEN1KCNQ2CASR
SCHEMBL7189152 0.73 NPSR1 (0.37) ALDH1A1ACP3TDP1L3MBTL1HPGD
SCHEMBL7183493 0.73 L3MBTL1 (0.38) ALDH1A1PBRM1FABP3FABP4FEN1
SCHEMBL7189380 0.73 KCNQ2 (0.43) ALDH1A1PBRM1FABP3FABP4FEN1
SCHEMBL9484289 0.73 FEN1 (0.37) ALDH1A1PBRM1FABP3FABP4FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ALDH1A1 3416/4885PBRM1 2235/4885FABP3 3252/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ALDH1A1 3984/4885PBRM1 1852/4885FABP3 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.